



13 May 2015

ASX ANNOUNCEMENT

Additional Major Cancer Centre in US Commercial L-Dex Program

Brisbane, Australia – **ImpediMed Limited** (ASX: IPD) ("the Company"), is pleased to announce the launch of an additional L-Dex® pilot with a prominent multi-specialty cancer centre in the US. This is the fourth of six planned cancer centre pilots.

The pilot program activities include integrating a prospective surveillance model for the early detection of cancer related lymphedema using L-Dex, capturing L-Dex scores in the electronic medical records (EMR), providing education and training for staff, patients, and referring physicians.

Program participants will provide ImpediMed a unique opportunity to gain insight into cancer centres through constructive feedback regarding implementation, integration, and patient use aspects of the L-Dex system in order to optimise the utility and benefits of the L-Dex system in this environment.

President and CEO Richard Carreon stated, "ImpediMed is pleased to expand the cancer centre pilot programs for L-Dex with this highly esteemed organisation. These pilot programs offer us invaluable insight into our market as we prepare for the full commercial launch of L-Dex in the US, which is scheduled for later in calendar year 2015. I am very pleased with our ongoing targeted launch as we continue our mission to improve the quality of life for cancer patients and to become the accepted standard of care in the early detection and early intervention for lymphoedema."

Richard Carreon
CEO

For further information contact:
Richard Carreon, ImpediMed CEO
Morten Vigeland, ImpediMed CFO
T: +1 (760) 585-2100

Kyahn Williamson, Buchan
Investor and Media Relations
T: +61 3 9866 4722
E: kwilliamson@buchanwe.com.au

About ImpediMed

ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and

monitoring of fluid status. ImpediMed's primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men.

For more information, visit: www.impedimed.com.au